Ladarixin sodium - 10mM in DMSO , CAS No.865625-56-5

CAS: 865625-56-5 Cat. No.: L656609 Molecular Weight: 397.32 EC Number: 691-863-8 PubChem CID: 23709380
AVAILABLE TO ORDER
GRADE & PURITY 10mM in DMSO
Storage
Desiccated,Store at -80°C
Shipped In
Dry ice packs + Cold packs
Size
Status
Price
Qty
1ml
L656609-1ml
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$660.90
Enter a quantity for the sizes you want to add.
🧪

Why this grade

10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Desiccated,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Overview

Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma

In Vitro

Ladarixin inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 (IC 50 at 0.7 nM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ladarixin (10 mg/kg; p.o. once a day) reduces allergic airway inflammation in a model of single OVA exposure. Ladarixin reduces allergic airway inflammation, remodeling, and bronchial hyperreactivity in a model of chronic OVA exposure . Ladarixin (10 mg/kg; p.o. once a day for 8 days) reduces pulmonary inflammation and fibrosis induced by bleomycin in mice . Ladarixin (10 mg/kg; p.o. once a day for 3 days) protects mice from cigarette smoke-induced exacerbation of influenza-A infection . Ladarixin is also effective in decreasing CXCL8-induced polymorphonuclear leukocyte infiltration in several animal models without a significant dose-related reduction in systemic neutrophil counts. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice (cigarette smoke-induced exacerbation of Influenza-A infection model) Dosage: 10 mg/kg Administration: P.o. once a day at days 2, 3 and 4 post-infection Result: Significantly attenuated the exacerbation in lethality and respiratory changes noted in CSFlu group.

IC50& Target:CXCR1 CXCR2

Specifications

Specifications & Purity
10mM in DMSO
Biochemical and Physiological Mechanisms
Ladarixin sodium (DF 2156A) is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma.
Storage
Desiccated, Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
ANTAGONIST
Names and Identifiers
Isomeric SMILES C[C@H](C1=CC=C(C=C1)OS(=O)(=O)C(F)(F)F)C(=O)[N-]S(=O)(=O)C.[Na+]
Alternate CAS 865625-56-5
PubChem CID 23709380
MeSH Entry Terms 2'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide;DF 2156A;DF 2156Y;DF-2156A;DF-2156Y;DF2156A;DF2156Y;ladarixin
Molecular Weight 397.32

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Certificates(CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Solution Calculators
Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.